Danaher Corporation (DHR)

Currency in USD
229.75
-4.11(-1.76%)
Closed·
232.02+2.27(+0.99%)
·
DHR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
228.17238.13
52 wk Range
160.93242.80
Key Statistics
Prev. Close
229.75
Open
233.8
Day's Range
228.17-238.13
52 wk Range
160.93-242.8
Volume
7.07M
Average Volume (3m)
4.43M
1-Year Change
3.1518%
Book Value / Share
76.28
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DHR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
258.86
Upside
+12.67%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 8 consecutive years

Danaher Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Analyst Ratings

20 Buy
4 Hold
0 Sell
Ratings:
24 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 258.86
(+12.67% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy270.00+17.52%255.00MaintainOct 22, 2026
UBS
Buy260.00+13.17%260.00MaintainOct 22, 2026
JPMorgan
Buy270.00+17.52%250.00MaintainOct 22, 2026
Stifel
Buy260.00+13.17%220.00MaintainOct 22, 2026
Baird
Buy254.00+10.55%246.00MaintainOct 22, 2026

Danaher Corporation SWOT Analysis


Life Sciences Leade
Danaher Corporation, a $150B market cap giant, dominates life sciences, diagnostics, and CROs sectors with robust financial health and strategic market positioning
Financial Trajectory
Analysts project steady growth for Danaher, with revenue expected to reach $27.67B by 2027 and EPS rising to $9.56, showcasing strong financial outlook
Strategic Evolution
Explore Danaher's proactive cost-saving measures and operational efficiencies, aimed at expanding margins into the mid-30s and enhancing shareholder value
Market Dynamics
Average analyst price target of $284, reflecting varied perspectives on Danaher's growth potential amid biotech recovery and ongoing challenges in China
Read full SWOT analysis

Danaher Corporation Earnings Call Summary for Q3/2026

  • Danaher reported Q3 2026 adjusted EPS of $2.11, beating estimates of $1.92, while revenue of $6.6B slightly topped forecasts; shares fell 3.67%.
  • Core revenue growth excluding respiratory products accelerated to 5.5% from 4.5% in Q2; respiratory sales created a 250 basis point drag on growth.
  • Full-year 2026 adjusted EPS guidance raised to $8.57-$8.62 from $8.45-$8.60; Q4 core growth expected at 4%-5% excluding respiratory products.
  • CEO Montgomery emphasized goal to become 'defining leader' in life sciences and diagnostics, highlighting AI-powered autonomous lab capabilities.
  • Management provided preliminary 2027 outlook of 4%-5% core growth excluding respiratory, with formal guidance expected in January; strong free cash flow of $4B YTD.
Last Updated: 21/10/2026, 14:14
Read Full Transcript

Earnings

Latest Release
Oct 21, 2026
EPS / Forecast
2.11 / 1.92
Revenue / Forecast
6.6B / 6.56B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 6.07
Dividend Yield
0.70%
Industry Median 1.48%
Annualised payout
1.60
Paid quarterly
5-Years Growth
+9.58%
Growth Streak

DHR Income Statement

Compare DHR to Peers and Sector

Metrics to compare
DHR
Peers
Sector
Relationship
P/E Ratio
37.7x25.7x−0.3x
PEG Ratio
1.48−0.150.00
Price/Book
3.0x2.6x2.6x
Price / LTM Sales
6.3x3.1x2.9x
Upside (Analyst Target)
12.7%−3.1%64.3%
Fair Value Upside
Unlock5.1%9.2%Unlock

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
321.49M45.73%75.18B
Other Institutional Investors
267.74M38.09%62.61B
Public Companies & Retail Investors
113.76M16.18%26.60B
Total
702.99M100.00%164.4B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.7.84%55,084,63012,882,092
Vanguard Capital Management, LLC6.39%44,919,68410,504,917

People Also Watch

827.42
GEV
-10.64%
443.85
ISRG
+3.67%
140.83
VST
-9.81%
279.50
TXN
-1.81%

FAQ

What Is the Danaher (DHR) Stock Price Today?

The Danaher stock price today is 229.75 USD.

What Stock Exchange Does Danaher Trade On?

Danaher is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Danaher?

The stock symbol for Danaher is "DHR."

What Is the Danaher (DHR) Afterhours Price Today? (Afterhours variable test: 229.34) Current Date: Oct 23, 2026

After hours price: 229.34. After hours price change (units): -0.41. Price change percentage: -0.18%

What Is the Danaher Market Cap?

As of today, Danaher market cap is 161.64B USD.

What Is Danaher's Earnings Per Share (TTM)?

The Danaher EPS (TTM) is 6.07.

When Is the Next Danaher Earnings Date?

Danaher will release its next earnings report on Feb 03, 2027.

From a Technical Analysis Perspective, Is DHR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Danaher Stock Split?

Danaher has split 5 times.

How Many Employees Does Danaher Have?

Danaher has 59000 employees.

What is the current trading status of Danaher (DHR)?

As of Oct 23, 2026, Danaher (DHR) is trading at a price of 229.75 USD, with a previous close of 229.75 USD. The stock has fluctuated within a day range of 228.17 USD to 238.13 USD, while its 52-week range spans from 160.93 USD to 242.80 USD.

What Is Danaher (DHR) Price Target According to Analysts?

The average 12-month price target for Danaher is 258.86 USD, with a high estimate of 310 USD and a low estimate of 205 USD. 20 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +12.67% Upside potential.

What Is the DHR Premarket Price?

DHR's last pre-market stock price is 232.02 USD. The pre-market share volume is 180.00, and the stock has decreased by 2.27, or 0.99%.

What Is the DHR After Hours Price?

DHR's last after hours stock price is 229.34 USD, the stock has decreased by -0.41, or -0.18%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.